Oligodendroglioma
62
14
19
16
Key Insights
Highlights
Success Rate
59% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
17.7%
11 terminated out of 62 trials
59.3%
-27.2% vs benchmark
8%
5 trials in Phase 3/4
56%
9 of 16 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 16 completed trials
Clinical Trials (62)
Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma
Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma
PRO-GLIO: PROton Versus Photon Therapy in IDH-mutated Diffuse Grade II and III GLIOmas
Investigational Imaging Technique During Brain Surgery
Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases
Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2
Pre-Radiation Chemotherapy for Newly Diagnosed High-Grade Glioma.
All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas).
A Randomized Trial of Delayed Radiotherapy in Patients Low-grade Oligodendrogliomas Requiring a Treatment Other Than Surgery
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
Peds CHAMP1ON - Hematopoietic Stem Cell And Monoclonal Antibody PD-1 Blockade for RecurreNt Pediatric High-Grade Glioma
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
HOBSCOTCH-CA (HOme-Based Self-management and COgnitive Training CHanges Lives in Brain CAncer)
CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot Trial
Evaluating the Expression Levels of MicroRNA-10b in Patients With Gliomas
FearLess in NeuroOncology